Literature DB >> 30758524

The significance of intraoperative renal pelvic urine and stone cultures for patients at a high risk of post-ureteroscopy systemic inflammatory response syndrome.

Satoshi Yoshida1, Ryoji Takazawa2, Yusuke Uchida1, Yusuke Kohno1, Yuma Waseda1, Toshihiko Tsujii1.   

Abstract

We examined the renal pelvic urine culture (RPUC) and stone culture (SC) during ureteroscopy and evaluated their associations with postoperative systemic inflammatory response syndrome (SIRS). We prospectively collected data of 224 patients who underwent ureteroscopic laser lithotripsy from March 2015 to December 2017. We examined the bladder urine culture pre-operatively. If the patients had positive culture results, we treated them with antibiotics for 5-7 days before surgery based on the sensitivity profile. We collected RPUC and SC samples during surgery. After ureteroscopy, patients were closely monitored for any signs of SIRS. Using a logistic regression model, we analyzed how the clinical factors affected the incidence of SIRS. Pre-operative bladder urine culture (PBUC) was positive in 111 patients (49.6%). Intraoperative RPUC was positive in 43 patients (19.2%), and SC was positive in 34 patients (15.2%). Postoperatively, 23 patients (10.3%) were diagnosed with SIRS. A multivariate analysis revealed that female gender, struvite calculi and positive intraoperative RPUC results were significantly associated with postoperative SIRS. Among the 31 patients who were positive for both PBUC and intraoperative RPUC, the pathogens were not consistent in 11 patients (35.5%). Among the 25 patients who were positive for both PBUC and intraoperative SC, the pathogens were not consistent in 13 patients (52.0%). We recommend collecting RPUC and SC samples during ureteroscopy, especially for patients with high risk factors, including female gender, expected struvite calculi and positive PBUC results.

Entities:  

Keywords:  Bladder urine culture; Renal pelvic urine culture; Stone culture; Systemic inflammatory response syndrome; Ureteroscopy

Mesh:

Year:  2019        PMID: 30758524     DOI: 10.1007/s00240-019-01112-6

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  17 in total

1.  Clinical implication of routine stone culture in percutaneous nephrolithotomy--a prospective study.

Authors:  D Margel; Y Ehrlich; N Brown; D Lask; P M Livne; D A Lifshitz
Journal:  Urology       Date:  2006-01       Impact factor: 2.649

2.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

Review 3.  Antibiotic use and the prevention and management of infectious complications in stone disease.

Authors:  Daniel A Wollin; Adrian D Joyce; Mantu Gupta; Michael Y C Wong; Pilar Laguna; Stavros Gravas; Jorge Gutierrez; Luigi Cormio; Kunjie Wang; Glenn M Preminger
Journal:  World J Urol       Date:  2017-02-03       Impact factor: 4.226

4.  Predictive risk factors for systemic inflammatory response syndrome following ureteroscopic laser lithotripsy.

Authors:  Yusuke Uchida; Ryoji Takazawa; Sachi Kitayama; Toshihiko Tsujii
Journal:  Urolithiasis       Date:  2017-07-10       Impact factor: 3.436

5.  Risk factors of infectious complications following flexible ureteroscope with a holmium laser: a retrospective study.

Authors:  Song Fan; Binbin Gong; Zongyao Hao; Li Zhang; Jun Zhou; Yifei Zhang; Chaozhao Liang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  Importance of microbiological evaluation in management of infectious complications following percutaneous nephrolithotomy.

Authors:  Hasan Serkan Dogan; Fuad Guliyev; Yesim S Cetinkaya; Mustafa Sofikerim; Ender Ozden; Ahmet Sahin
Journal:  Int Urol Nephrol       Date:  2007-02-10       Impact factor: 2.370

7.  Outcomes of Flexible Ureterorenoscopy for Solitary Renal Stones in the CROES URS Global Study.

Authors:  Andreas Skolarikos; Andreas J Gross; Alfred Krebs; Dogan Unal; Eduardo Bercowsky; Ehab Eltahawy; Bhaskar Somani; Jean de la Rosette
Journal:  J Urol       Date:  2015-02-09       Impact factor: 7.450

8.  Systemic inflammatory response syndrome after flexible ureteroscopic lithotripsy: a study of risk factors.

Authors:  Wen Zhong; Gioacchino Leto; Liang Wang; Guohua Zeng
Journal:  J Endourol       Date:  2015-01       Impact factor: 2.942

Review 9.  EAU Guidelines on Interventional Treatment for Urolithiasis.

Authors:  Christian Türk; Aleš Petřík; Kemal Sarica; Christian Seitz; Andreas Skolarikos; Michael Straub; Thomas Knoll
Journal:  Eur Urol       Date:  2015-09-04       Impact factor: 20.096

10.  Analysis of Factors' Association with Risk of Postoperative Urosepsis in Patients Undergoing Ureteroscopy for Treatment of Stone Disease.

Authors:  James P Blackmur; Neil U Maitra; Rajendar R Marri; Fadi Housami; Manar Malki; Craig McIlhenny
Journal:  J Endourol       Date:  2016-07-13       Impact factor: 2.942

View more
  3 in total

1.  Albumin-globulin ratio: a novel predictor of sepsis after flexible ureteroscopy in patients with solitary proximal ureteral stones.

Authors:  Junlin Lu; Yang Xun; Xiao Yu; Zheng Liu; Lei Cui; Jiaqiao Zhang; Cong Li; Shaogang Wang
Journal:  Transl Androl Urol       Date:  2020-10

2.  The Risk Factors of Febrile Urinary Tract Infection After Ureterorenoscopic Lithotripsy.

Authors:  Futoshi Morokuma; Eiji Sadashima; Soutaro Chikamatsu; Tomoya Nakamura; Yusuke Hayakawa; Noriaki Tokuda
Journal:  Kobe J Med Sci       Date:  2020-09-10

3.  Expression of Inflammatory Factors in Critically Ill Patients with Urosepticemia and the Imaging Analysis of the Severity of the Disease.

Authors:  Xia Huang; Zongjun Hu; Xi Yue; Yong Cui; Jiwen Cui
Journal:  J Healthc Eng       Date:  2021-02-20       Impact factor: 2.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.